
KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Declining Childhood Vaccinations Could Increase Frequency of Infectious Disease Previously Eliminated April 25, 2025The findings support the need for improved vaccination coverage to prevent the resurgence of previously eliminated infectious diseases in the United States.
- The Current State Of OTC Medication Use for Pain Management April 24, 2025Leveraging his expertise in pain management, Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, joined Drug Topics to discuss the importance of pharmacists in patients’ use of OTC medications to treat pain.
- Cobenfy Did Not Meet Primary Outcome as Add-On Treatment for Schizophrenia April 24, 2025However, the results show that there was an improvement of symptom scores, although they were not significant.
- As Measles Outbreak Continues, Misinformation Continues to Grow April 24, 2025In a new survey, approximately one-third of respondents have heard that the MMR vaccine is more dangerous than being infected with the infection.
- The Impact of Increased Drug Advertising on Patients, Consumers April 23, 2025Expert in drug markets, Luke Turnock, PhD, joined Drug Topics to assess where he thinks recent trends in drug advertising will lead patients in the near-to-long-term future.
- Hormonal Contraceptive Use Increases Risk of Depression April 23, 2025Researchers explored whether or not hormonal contraceptive initiation is associated with increased risk of developing depression within 12 months of child delivery.
- Pharmacist’s Knowledge, Attitudes, Beliefs Influence Patients Receiving Vaccination April 23, 2025Investigators specifically analyze information on influenza and pneumococcal vaccinations.
- Study: CGMs Show Promise in Early Diagnostic of Type 2 Diabetes April 22, 2025This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.
- SureCost for Health System Pharmacies: How to Save 2-5% on Cost of Goods (COGs) April 22, 2025Learn how SureCost empowers health system pharmacies to save more with data-driven cost management and expanded vendor options. Discover how integrated procurement and inventory tools help you work smarter by reducing inefficiencies and simplifying operations. SureCost also ensures compliance with primary vendor, GPO, and manufacturer obligations—holding all vendors accountable and aligning your team around a […]
- As a Result of PBM Reform, CVS Will Close Over 20 Pharmacies in Arkansas April 22, 2025CVS releases a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.
Pharmacy Times articles
- Expert: Pharmacists' Role in Education, Adoption, and Market Sustainability for Biosimilars April 27, 2025Pharmacists play a crucial role in advancing biosimilar adoption through targeted education, addressing misconceptions about safety and efficacy.
- AACR 2025: Off-the-Shelf Machine Learning Models May Bridge Diagnostic Gaps in Global Skin Cancer Care April 27, 2025Pretrained foundation machine learning models significantly improved the accuracy of diagnosing non-melanoma skin cancer from digital pathology images and may offer a practical, resource-efficient solution for cancer diagnosis in underserved settings.
- AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML April 27, 2025Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
- AACR 2025: Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-Mutated NSCLC April 27, 2025Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.
- Hydroxyurea Produces Long-Term Clinical Benefits in Pediatrics With Sickle Cell Anemia April 26, 2025New research confirms hydroxyurea's long-term effectiveness in reducing hospital visits for children with sickle cell anemia, supporting its use as standard treatment.
- NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025 April 25, 2025NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.
- DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy April 25, 2025
- AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia April 25, 2025Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements.
- Asembia's AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers April 25, 2025The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.
- NCPA Urges DOGE to Examine PBMs for Waste, Fraud, and Abuse April 25, 2025Government doles out billions to PBMs to stabilize premiums, but premiums keep rising along with PBM profits.

Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com